Clinical trial · Observational
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
NCT03209492CI-TRIAL-00038076completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Leuprorelin acetate | Drug | Leuprolide | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Leuprorelin acetate
- description
- Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
- interventionNames
- Drug: Leuprorelin acetate
Primary outcomes (1)
- measure
- Percentage of Participants Who Had One or More Adverse Events
- timeFrame
- Up to Week 24
Secondary outcomes (1)
- measure
- Percentage of Participants Who Had One or More Adverse Reactions
- timeFrame
- Up to Week 24
- description
- Adverse drug reaction refers to adverse events related to the administered drug.
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Participants with prostate cancer will be included. Exclusion Criteria: * Participants with previous history of hypersensitivity to any of the ingredients of the drug or synthetic LH-RH or LH-RH derivatives
References
Publications (0)
Data not yet available
No reference posted for this study.